# Nan Ji

> Nan Ji is co-founder, president and CEO of PAQ Therapeutics, a Burlington, Massachusetts clinical-stage biotech pioneering autophagosome-tethering compounds (ATTECs) to degrade KRAS and other 'undruggable' disease drivers. A Harvard-trained organic chemist with 30+ patent applications, he spent seven years at Novartis, helped build Kymera Therapeutics from seed stage as VP of Chemistry, and launched PAQ in 2020 to hijack the body's natural cellular clean-up machinery for cancer and neurodegenerative disease.

- **Role:** Co-Founder, President and CEO at PAQ Therapeutics
- **Organizations:** PAQ Therapeutics, Kymera Therapeutics (former), Mitobridge (former), Novartis Institutes for BioMedical Research (former), Harvard University (alumnus), Peking University (alumnus)
- **Education:** B.S., Organic Chemistry, Peking University, Ph.D., Organic Chemistry, Harvard University, Postdoctoral Fellow, Harvard University
- **Known for:** Co-founded and leads PAQ Therapeutics, a clinical-stage biotech advancing autophagosome-tethering compound (ATTEC) drug discovery, Raised over $111M in venture financing across Series A and B rounds, Named on 30+ patent applications in medicinal chemistry and targeted degradation

## Career timeline

- **2008-2015** — Investigator II then Investigator III, Novartis Institutes for BioMedical Research
- **2015-2017** — Senior Scientist, then Associate Director, Mitobridge (acquired by Astellas)
- **2017-2020** — Director then Executive Director then VP/Head of Chemistry, Kymera Therapeutics (from seed stage)
- **2020** — Co-founded PAQ Therapeutics with Boxun Lu and Huaixiang Hao
- **2021** — Closed $30M Series A led by Sherpa Health / MRL Ventures et al.
- **2021** — Announced collaboration with Insilico Medicine on autophagy-dependent degradation
- **2025** — Announced $39M Series B; initiated Phase 1 trial in KRAS-driven cancers
- **2026** — Series B extension brings round to $77M; first patient dosed with PT0511, a pan-KRAS degrader

## Achievements

- Co-founded and leads PAQ Therapeutics, a clinical-stage biotech advancing autophagosome-tethering compound (ATTEC) drug discovery
- Raised over $111M in venture financing across Series A and B rounds
- Named on 30+ patent applications in medicinal chemistry and targeted degradation
- Advanced PT0511, a pan-KRAS degrader, into a first-in-human Phase 1 clinical trial
- Built Kymera Therapeutics' chemistry organization from seed stage through Vice President-level leadership
- Contributed to multiple clinical and preclinical development candidates during 7+ years at Novartis

## Latest updates

- **2026-01** — PAQ Therapeutics closed a Series B extension bringing the round to $77M; first patient dosed in Phase 1 trial of PT0511, a pan-KRAS degrader.
- **2025-05** — PAQ announced $39M Series B financing and initiation of Phase 1 trial in KRAS-driven cancers.

## Links

- Website: https://www.paqtx.com
- LinkedIn: https://www.linkedin.com/in/nan-ji-a7a64b3

---

Profile page: https://yespress.io/nan-ji
Published by YesPress — https://yespress.io
Last updated: 2026-07-09